Treatment of Familial Hypercholesterolemia and Familial Defective apoB-100
Author Information
Author(s): Leren Trond P., Berge Knut Erik
Primary Institution: Oslo University Hospital Rikshospitalet, Oslo, Norway
Hypothesis
Are subjects with a molecular genetic diagnosis of familial hypercholesterolemia (FH) or familial defective apoB-100 (FDB) being adequately treated?
Conclusion
The majority of FH/FDB subjects are being diagnosed late in life and are not being adequately treated.
Supporting Evidence
- Only 47.3% of subjects were considered adequately treated.
- Among those below 18 years, only 20.4% were on lipid-lowering drugs.
- 89.1% of those aged 18 and above were on lipid-lowering drugs.
- 29.0% of those on treatment had LDL cholesterol below 3.0 mmol/l.
- Mean age for starting lipid-lowering therapy was 33.4 years.
Takeaway
Kids with a genetic condition that makes their cholesterol high aren't getting the medicine they need, which can lead to heart problems when they grow up.
Methodology
A questionnaire was sent to 2611 subjects with a genetic diagnosis of FH or FDB, and blood samples were taken for lipid measurements.
Potential Biases
Self-reported medical history may introduce uncertainties regarding the quality of the information.
Limitations
Only 36.6% of those invited participated, which may lead to selection bias.
Participant Demographics
The mean age of participants was 44.3 years, with 534 females and 422 males.
Statistical Information
P-Value
p<0.0001
Statistical Significance
p<0.0001
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website